Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Eisai Says It Still Has Patent Protection For Aricept Despite Court Action (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japan's Eisai says a U.S. district court ruling will have no impact on the validity of its patent for Aricept (donepezil hydrochloride) for treating Alzheimer's disease. The court in New Jersey threw out Eisai's suit against Mutual Pharmaceutical for seeking U.S. FDA approval for an Aricept generic. Eisai said the ruling was based on procedural grounds and it is still free to sue Mutual to defend a patent not set to expire until 2010. (Click here for more - may require a subscription

You may also be interested in...



Coronavirus Update: Moderna Still Confident Of November Readout

The company said its own calculations suggest a mid-November readout could yield a positive result, keeping it on track for an EUA before the end of 2020.

Latest European Commission Document Focuses On New Rapid Antigen Tests for COVID-19

With COVID-19 continuing to wreak havoc in the EU just as throughout the globe, the European Commission is proposing new measures that will impact antigen test availability and use

Amgen Warns Against Conflating Oncology And Inflammation Biosimilars

Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel